Director, Reimbursement Policy & Access Strategy

Takeda; Washington (District of Columbia); Hybrid; USD 154,000 - 243,000; Full time

Benefits offered by this job

Travel up to 10%

Job summary

Takeda seeks an Associate Director, Public Policy and Reimbursement to lead reimbursement policy and analysis for the U.S. portfolio. You will partner with the U.S. Public Affairs team to shape strategy and engage stakeholders in a hybrid role based in Washington, D.C. or Cambridge, MA.

Responsibilities include analyzing CMS policies, leading coding initiatives, and guiding MFN, 340B, and Inflation Reduction Act considerations to inform pricing and access decisions.

Qualifications

• Bachelor’s degree is required.
• 7+ years of professional experience within the pharmaceutical industry.
• Strong writing skills; a writing sample will be required.

Responsibilities

• Analyze federal and commercial coverage, coding, and payment policies and assess implications for Takeda's U.S. portfolio.
• Monitor and interpret evolving reimbursement and access policies across Medicare, Medicaid, and commercial markets.
• Develop reimbursement policy positions with actionable recommendations for business decisions.
• Lead and support reimbursement, coverage, coding, and access strategies across portfolios.
• Engage CMS and coding initiatives, including HCPCS, CPT, and USP classifications.
• Collaborate cross-functionally to evaluate policy developments and drive alignment.

Skills

Reimbursement knowledge

Payer environments

FDA/regulatory awareness

Product development

Project management

Analytical skills

Communication skills

Education

Bachelor's degree

Job description

Takeda seeks an Associate Director, Public Policy and Reimbursement to lead reimbursement policy and analysis for the U.S. portfolio. You will partner with the U.S. Public Affairs team to shape strategy and engage stakeholders in a hybrid role based in Washington, D.C. or Cambridge, MA.

Responsibilities include analyzing CMS policies, leading coding initiatives, and guiding MFN, 340B, and Inflation Reduction Act considerations to inform pricing and access decisions.